Skip to main content

Regulus Therapeutics Inc.

RGLSDelisted Jun 25, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001505512

Regulus Therapeutics Inc. was delisted on Jun 25, 2025; its insiders filed their last Form 4 on Jun 27, 2025; 75 institutions reported holding it in 13F filings for Q1 2025, worth $107.0M in total; no superinvestor held it.

Q3 2021 vs. Q2 2021

How the institutions holding Regulus Therapeutics Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021All holders in Q2 2021

13F holders of RGLS: Q2 2021 compared with Q3 2021
MeasureQ2 2021Q3 2021Change
Holders4542−3
Shares23.1M23.0M−101.8K (−0.4%)
Value$18.7M$15.9M−$2.88M (−15.4%)

New holders (6)

Institutions that held Regulus Therapeutics Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to RGLS in Q3 2021
InstitutionSharesValue% of portfolio
Price T Rowe Associates Inc38,100$26.0K0.00%
UBS Group AG19,874$14.0K0.00%
Cambridge Investment Research Advisors, Inc.14,000$10.0K0.00%
Two Sigma Advisers, LP11,900$8.00K0.00%
AdvisorNet Financial, Inc7,500$5.00K0.00%
Barclays PLC50$00.00%

Sold out (9)

Institutions that held Regulus Therapeutics Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of RGLS in Q3 2021
InstitutionShares, Q2 2021Value, Q2 2021
Focused Wealth Management, Inc200,000$163.0K
Tower Research Capital LLC (TRC)91,872$75.0K
Virtu Financial LLC79,193$64.0K
Strategic Wealth Advisors Group, LLC74,800$61.0K
Jane Street Group, LLC59,432$48.0K
Two Sigma Securities, LLC37,741$31.0K
Zacks Investment Management28,346$23.0K
Pinz Capital Management, LP22,300$18.0K
Endurance Wealth Management, Inc.6,750$5.00K